AstraZeneca Plc (NASDAQ: AZN) surges over 5.84% to $68.12 in pre trading session on Thursday after The company forecasted growth in earnings and revenue in 2023 as it seeks to offset declining sales of COVID-19 medicines with cancer, metabolic, and rare disease drugs. Its shares rose 5% in early trade to rank second on London's blue-chip FTSE 100 index, on track for their best day in a year. According to CEO Pascal Soriot, the company is on track to release at least 15 new medicines this decade. After reporting a second...